News Releases header image
 |
|
This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence...
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 financial results on Thursday, October 22, 2026,...
Study published in JAMA Network Open of over 193,000 patients nationwide reveals that individuals with evidence of exposure to Borrelia burgdorferi, the bacterium that causes Lyme disease, are...
75% of registered voters surveyed call diagnostic testing "very important" to their care, and a bipartisan majority wants Congress to pass the RESULTS Act before additional Medicare cuts are...
Coming later this year, Apple Health app users will be able to conveniently and securely purchase and receive results of Quest's biomarker lab testing directly in the app SECAUCUS, N.J., Sept. 9, 2026
Individuals in the U.S. can now add Humanity Biological Age’s lab-informed insights to select health profile tests purchased through Quest’s consumer-initiated testing platform LONDON, August...
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance...
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's...
Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patients Quest also launching a new multi-biomarker AD-Detect® lab-developed blood test...
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October...
